MediciNova (MNOV)
(Delayed Data from NSDQ)
$1.37 USD
-0.02 (-1.44%)
Updated Jun 7, 2024 03:15 PM ET
After-Market: $1.36 -0.01 (-0.73%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
MediciNova, Inc. [MNOV]
Reports for Purchase
Showing records 21 - 40 ( 55 total )
Company: MediciNova, Inc.
Industry: Medical - Biomedical and Genetics
Company: MediciNova, Inc.
Industry: Medical - Biomedical and Genetics
Company: MediciNova, Inc.
Industry: Medical - Biomedical and Genetics
Company: MediciNova, Inc.
Industry: Medical - Biomedical and Genetics
Company: MediciNova, Inc.
Industry: Medical - Biomedical and Genetics
Company: MediciNova, Inc.
Industry: Medical - Biomedical and Genetics
Company: MediciNova, Inc.
Industry: Medical - Biomedical and Genetics
Company: MediciNova, Inc.
Industry: Medical - Biomedical and Genetics
Company: MediciNova, Inc.
Industry: Medical - Biomedical and Genetics
Company: MediciNova, Inc.
Industry: Medical - Biomedical and Genetics
Company: MediciNova, Inc.
Industry: Medical - Biomedical and Genetics
Company: MediciNova, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: MediciNova, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: MediciNova, Inc.
Industry: Medical - Biomedical and Genetics
We are terminating coverarge of Medicinova due to the departure from the firm of covering analyst
Provider: RODMAN & RENSHAW, CO.
Company: MediciNova, Inc.
Industry: Medical - Biomedical and Genetics
MN-221 Phase 2b Trial Results in Asthma Exacerbations
Provider: RODMAN & RENSHAW, CO.
Analyst: PIROS E
Company: MediciNova, Inc.
Industry: Medical - Biomedical and Genetics
MN-221 Phase 2b Trial Results in Asthma Exacerbations
Provider: RODMAN & RENSHAW, CO.
Analyst: PIROS E